(Sharecast News) - Molecular diagnostics group Yourgene has inked a licence and supply agreement with an unnamed American precision medicine company.
Yourgene said on Wednesday that the agreement, which has an initial term of three years, grants the mystery partner a non-exclusive licence to the company's Flex analysis software and commits it to supplying sample preparation reagents and instrumentation to support the planned launch of a new clinical reproductive health screening service across all US states.
Chief executive Lyn Rees said: "We are extremely pleased to sign this agreement with such a prestigious US company and this is a strong endorsement of our software and technology expertise. This collaboration aligns with our strategic goal of providing partners with the best-in-class instrumentation and medical software analysis capabilities.
"We look forward to enabling our partner to launch a competitive clinical offering into the US market in 2022 and we anticipate that this partnership will generate accretive multi-million dollar revenues for Yourgene in the years to follow. Our move into the US market space is gaining momentum and our newly acquired Ranger Technology is proving to be a real door opener."
As of 0955 BST, Yourgene shares were up 0.19% at 13.52p.
26 Oct 2020 10:02
Yourgene Health interim revenues grow despite Covid-19 headwinds
(Sharecast News) - Molecular diagnostics group Yourgene Health said on Monday that interim revenues had risen as a strong showing from its European unit had offset much of the headwinds stemming from the Covid-19 pandemic.
Read more